TherapeuticsMD: The Most Undervalued Drug/Device/Biotech Commercial Manufacturer In A Generation
Seeking Alpha,
Summary TXMD trades at ~3.5X consensus 2020 revenue estimates vs. 10X for like peers.
Summary TXMD trades at ~3.5X consensus 2020 revenue estimates vs. 10X for like peers.
Summary The company is awaiting FDA minutes due on July 14, 2017. High likelihood of FDA approval with the approach the company…